Cohort characteristics: inflammatory and oxidative stress markers, adipokines and advanced glycation end products.

Central obesity: waist-to-height ration >0.5 [31]; elevated BP: systolic BP (SBP)≥130 mm Hg and/or diastolic BP (DBP)≥85 mm Hg; increased atherogenic risk: AIP≥0.11 [29]; and insulin resistance: QUICKI<0.322 were considered as factors indicated increased cardiometabolic risk. 0: no risk factor presented (n = 162); 1–2: subjects with 1 or 2 risk factors (n = 162); 3–4: subjects presenting 3 or 4 risk factors (n = 87); hsCRP: high sensitive C-reactive protein; IL-6: interleukine-6; hsTNF-α: high sensitive tumor necrosis factor-α; CML: Nε-(carboxymethyl)lysine; Alb: albumin; AGE-Fl: advanced glycation end products associated fluorescence of plasma; AU: arbitrary units; AOPP: advanced oxidation protein products; sRAGE: soluble receptor for advanced glycation end products
*: p<0.05 vs. cardiometabolic risk factors free subjects
**: p<0.01 vs. cardiometabolic risk factors free subjects
***: p<0.001 vs. cardiometabolic risk factors free subjects
+: p<0.05 vs. subjects presenting 1 or 2 cardiometabolic risk factors
++: p<0.01 vs. subjects presenting 1 or 2 cardiometabolic risk factors
+++: p<0.001 vs. subjects presenting 1 or 2 cardiometabolic risk factors; italics: statistical evaluation performed on logarithmically transformed data
Cohort characteristics: inflammatory and oxidative stress markers, adipokines and advanced glycation end products.